For the Inventor, By the Inventor

Enter inventor name

Shanghai, China

Zhengxia Chen

USPTO Granted Patents = 17 (Patent Applications = 8)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 23)

Average Co-Inventor Count = 7.7

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Dongguan, CN (2020)
Shanghai, CN (2016 - 2024)

Company Filing History:

Merck Sharp + Dohme Corp.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Cgenetech (suzhou, China) Co., Ltd.

Medshine Discovery Inc.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

Wuxi Life Fountain Biotech Co., Ltd

Shenzhen Lingfang Biotech Co., Ltd.

Novaonco Js Therapeutics Co., Ltd.

Cspc Zhongqi Pharmaceuticall Technology (shijiazhuang) Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Guangdong Xianqiang Pharmaceutical Co., Ltd

Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.

Yaopharma Co., Ltd.

15. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Loading Chart...

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378241 - Pyridine derivative as FGFR and VEGFR dual inhibitors (2025-08-05),

2. 12325703 - Fused ring compound as FGFR and VEGFR dual inhibitor (2025-06-10),

3. 12312347 - Azaindole derivative and use thereof as FGFR and C-Met inhibitor (2025-05-27),

4. 12297197 - Pyrazolopyridine compound as RET inhibitor and application thereof (2025-05-13),

5. 12152013 - Vinylpyridine carboxamide compound as PD-L1 immunomodulator (2024-11-26),

6. 11919898 - Crystal form of azaindole derivative and use thereof (2024-03-05),

7. 11440903 - Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof (2022-09-13),

8. 11236094 - Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors (2022-02-01),

9. 11161817 - Quinoline derivative and use thereof as tyrosine kinase inhibitor (2021-11-02),

10. 11078194 - Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor (2021-08-03),

11. 11008292 - FGFR4 inhibitor and preparation method and use thereof (2021-05-18),

12. 10766862 - Crystal form and salt form of and preparation method for tyrosine kinase inhibitor (2020-09-08),

13. 10654808 - Tyrosine kinase inhibitor and pharmaceutical composition comprising same (2020-05-19),

14. 10519133 - Vinyl compounds as FGFR and VEGFR inhibitors (2019-12-31),

15. 10000454 - Antidiabetic tricyclic compounds (2018-06-19),

Title: Zhengxia Chen - Pioneering Inventor from Shanghai

Introduction: Zhengxia Chen is a renowned inventor hailing from Shanghai, China, known for his groundbreaking contributions to various technological fields.

Latest Patents: Zhengxia Chen holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Zhengxia Chen has worked with leading research institutions and multinational companies, consistently pushing the boundaries of technological advancement.

Collaborations: Throughout his career, Zhengxia Chen has collaborated with top universities and innovative startups, fostering a culture of creativity and forward thinking in the industry.

Conclusion: Zhengxia Chen's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a trailblazer in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…